UCLA Health joins BriaCell’s phase 3 breast cancer study

PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX: BCT), a clinical-stage biotechnology company with a market capitalization of $2.5 million and an overall "WEAK" InvestingPro Financial Health score of 1.36, announced Thursday that UCLA Health Jonsson Comprehensive Cancer Center has joined its pivotal Phase 3 clinical study evaluating Bria-IMT in combination with a checkpoint inhibitor for advanced metastatic breast cancer.

The study, known as Bria-ABC, compares the Bria-IMT combination regimen against physician’s choice in patients with advanced metastatic breast cancer. UCLA Health represents a significant addition to the trial’s clinical sites. According to InvestingPro data, the company is rapidly burning through cash, with a negative free cash flow yield of -1.41% in the last twelve months.

"The randomized Phase 2 data reported with the Bria-IMT combination regimen are encouraging," said Dr. Kelly E. McCann, Breast Medical Oncologist and Lead Investigator at UCLA Health Jonsson Comprehensive Cancer Center.

Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer, stated the company remains confident in its timeline for sharing top-line data in 2026. An interim analysis will be conducted after 144 patient events have occurred, with overall survival as the primary endpoint. The company’s next earnings report is scheduled for August 28, 2025, with analysts not anticipating profitability this year. Get deeper insights into BriaCell’s financial outlook with InvestingPro, which offers 5 additional key insights about the company’s performance.

The trial design builds upon data from BriaCell’s Phase 2 study presented at ASCO 2025. The Bria-IMT combination regimen has received FDA Fast Track designation, according to the company’s press release statement.

BriaCell Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. The study is registered under ClinicalTrials.gov identifier NCT06072612.

In other recent news, BriaCell Therapeutics Corp. has reported significant developments in its ongoing cancer research efforts. The company announced a 52% one-year survival rate in its Phase 2 clinical study of Bria-IMT for metastatic breast cancer, surpassing expectations set by current standard therapies. Additionally, BriaCell’s Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor will continue without modifications after a positive safety review by the independent Data Safety Monitoring Board. The company has also expanded its Phase 3 clinical study by adding the Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, increasing the total number of clinical sites to 58 across 15 states.

Furthermore, BriaCell has completed the safety evaluation phase of its Bria-OTS immunotherapy in a Phase 1/2 monotherapy study and has begun testing it in combination with a checkpoint inhibitor. In a related development, BriaCell was granted a New Zealand patent for its whole-cell cancer immunotherapy technology, which ensures exclusivity until 2037. This patent covers methods of selecting immunotherapy for cancer patients based on HLA allele profile matching. These recent advancements highlight BriaCell’s ongoing commitment to advancing cancer treatment options.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.